HB 1117 requires Maryland's Medicaid program (Maryland Medical Assistance Program) and certain insurers to cover approved "elopement response devices" for specific individuals. These devices - such as door sensors, wearable location trackers, or alert systems - prevent people with cognitive, developmental, or neurological conditions from wandering unsafely (e.g., leaving a supervised area without the ability to return safely). Coverage is mandated when ordered by a qualified healthcare provider and documented in a qualifying plan (like an individualized education plan or dementia care plan) for eligible recipients: those under 21 with early screening eligibility, on home-based waiver programs, or diagnosed with Alzheimer’s/dementia. The bill defines these devices as medical equipment or assistive technology under state programs, ensuring coverage without regard to when the program was established.
HB 1292 requires child advocacy centers in Maryland to ensure all health care professionals providing medical or mental health services are properly licensed or certified and work within their scope of practice. It mandates that centers establish a "continuity of care plan" to notify families when providers change, including contact information for both new and former providers, and allows former providers to assist with care transitions per professional standards. Centers must report specific violations to health occupations boards or the Governor’s Office of Crime Prevention and Policy, and the Governor’s Office must publish annual data about child advocacy centers online. This bill directly affects child advocacy centers, their health care staff, and the children and families receiving services at these centers.
This bill requires health insurers and health plans in Maryland to cover salpingectomy (surgery to remove fallopian tubes) specifically for ovarian cancer prevention as a standard benefit, with no out-of-pocket costs like copays or deductibles for patients. It applies to all health insurance policies issued in Maryland after January 1, 2027, directly affecting women who might choose this preventive surgery and the insurers providing coverage. The key provision bans cost-sharing for this procedure, except when an individual is enrolled in a high-deductible health plan meeting federal criteria. This ensures access to a proven preventive measure without financial barriers for most patients.
This bill requires Maryland counties with volunteer fire companies to provide no-cost preventive cancer screenings to volunteer firefighters, as defined by the bill. Volunteer fire companies must maintain and annually submit a list of their volunteer firefighters to the county, which must then keep this list on file. Counties can meet this requirement by either offering a free annual health exam including cancer screenings or applying for a specific grant to fund advanced screening technologies like multi-cancer blood tests. The law applies to all counties with volunteer fire companies and takes effect July 1, 2026.
HB 1426 creates a new permit for clinical research pharmacies in Maryland, which are facilities specifically designed to conduct clinical trials. It allows healthcare providers to own these pharmacies under strict conditions, including requiring a licensed pharmacist to be on-site during all operating hours and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations or entities from being classified as "practice of medicine," meaning trial staff no longer need individual medical licenses for their trial-related work. This change aims to streamline clinical research by removing a regulatory barrier that previously required individual licensing for trial staff.
HB 222 requires Maryland public schools and colleges to update policies and education programs to address opioid overdoses. It mandates schools to store naloxone, allow authorized staff and students to possess it, and provide liability protection for good-faith use during overdoses. The bill also adds naloxone's life-saving role to K-12 drug prevention curricula (starting in third grade) and requires annual parent notifications about school naloxone policies. Additionally, schools must report overdose incidents requiring naloxone use to the State Department. This affects all public K-12 schools and state-funded colleges.
HB 494 requires health insurance companies, nonprofit health service plans, and health maintenance organizations (HMOs) operating in Maryland to structure their reimbursements to primary care providers in a way that meets annual investment targets set by the state. Starting February 1, 2026, these entities must report their progress toward meeting these targets when filing new or updated premium rates with the Maryland Insurance Commissioner. The bill amends insurance code sections to mandate this reporting requirement as part of premium rate filings. It takes effect October 1, 2026, focusing on transparency and accountability for primary care funding.
HB 417 (Public Health - Medetomidine and Xylazine Consumer Protection Act) regulates the sale of veterinary drugs medetomidine and xylazine. It prohibits retailers from selling these products without proof the buyer intends to use them for veterinary, scientific, or institutional purposes, and bans sales to anyone under 21. Retailers must maintain records of sales, including age verification and proof of intended use. Violations carry civil fines up to $6,500 per offense, with penalties deposited into Maryland's Substance Abuse Fund. The bill directly affects pharmacies, veterinary suppliers, and online retailers selling these specific products.
HB 633 requires Maryland health insurers, nonprofit health plans, and health maintenance organizations to cover salpingectomy (surgical removal of fallopian tubes) as a preventive measure for ovarian cancer. It prohibits these insurers from charging copayments, coinsurance, or deductibles for this specific procedure, ensuring no out-of-pocket costs for covered individuals. The exception applies only to high-deductible health plans under federal law, allowing the deductible to apply to the procedure in those cases. This law directly affects women eligible for preventive care and the health insurance providers operating in Maryland.
SB 489 modifies Maryland's licensing rules for physicians trained at international medical schools. It exempts applicants who provide evidence of completing two years of postgraduate training accredited by ACGME-I or another board-recognized body from standard educational requirements. These physicians would be permitted to practice medicine only during their initial license term under mandatory supervision, as specified by the Board. The bill takes effect October 1, 2026, directly affecting international medical graduates meeting these specific training criteria.
